BrainsWay Launches Social Media Sweepstakes in Observance of Depression Awareness Month
The sweepstakes aims to raise awareness of Deep TMS™ as a treatment option for mental health disorders so patients #DontMissAnotherMoment...
Mental Health
BrainsWay and NOCD Launch Collaboration to Increase Awareness of OCD Treatments
BURLINGTON, Mass. and JERUSALEM, Oct. 11, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
VitalHub Corp. Announces Acquisition of Community Data Solutions
TORONTO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- VITALHUB CORP. (TSX: VHI) (the “Company” or “VitalHub”) is pleased to announce today...
CloudMD Announces Divestment of Primary Care Clinics and Cloud Practice to WELL Health
VANCOUVER, British Columbia, Oct. 11, 2022 (GLOBE NEWSWIRE) -- CloudMD Software & Services Inc. (TSXV: DOC, OTCQX: DOCRF, Frankfurt: 6PH)...
Axsome Therapeutics Voices its Commitment to Mental Health on World Mental Health Day 2022
NEW YORK, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel...
Odyssey Health, Inc. Announces Successful Completion of Phase I Clinical Trial for Concussion Drug
Las Vegas, Nevada, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a...
VitalHub Announces Multi Year Contract With NHS Mid and South Essex ICB
TORONTO, Sept. 28, 2022 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSX: VHI) is pleased to announce a...
ReWalk Takes Another Step Toward Medicare Coverage
ReWalk to submit first cases for Medicare coverage through Medicare Administrative Contractors (MACs)Centers for Medicare and Medicaid Services (CMS) affirms...
BrightInsight Adds Xealth, Woebot Health and Claritas Rx to the BrightInsight Ecosystem
Companies Will Collaborate to Drive Digital Innovation, Adoption and EngagementSAN JOSE, Calif., Sept. 27, 2022 (GLOBE NEWSWIRE) -- BrightInsight, Inc.,...
BetterLife Files Comprehensive Patent for BETR-001 and Other LSD Derivatives
VANCOUVER, British Columbia, Sept. 27, 2022 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF...
Neuronetics Launches Innovations To NeuroStar® Advanced Therapy’s Proprietary TrakStar® Platform
Upgrades will enhance and automate the patient candidate experience for all NeuroStar providers, leading to faster patient identification of those...
Optimi Health, ATMA Journey Centers To Proceed With Phase I Natural Psilocybin and MDMA Clinical Trial Application to Health Canada
Optimi aiming to become the first vertically integrated psychedelics firm to formulate and trial MDMA for healthy subjectsVANCOUVER, British Columbia,...
Gather Behavioral Health Launches to Meet Growing Need for In-Person and Virtual Outpatient Therapy and Nutrition Services
ST. PAUL, Minn. and EAU CLAIRE, Wis., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Gather Behavioral Health, an outpatient practice offering...
Psyence Group Completes Export of Psilocybin Mushrooms to Canada
TORONTO, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”) has...
BrainsWay CEO Christopher von Jako Named Honorary Chair of NAMIWalks Silicon Valley
BURLINGTON, Mass. and JERUSALEM, Sept. 20, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
QHSLab, Inc. Launches a “Long COVID” Digital Health Tool for Primary Care Physicians
Primary care physicians now have access to reimbursable digital tools for the routine assessment of post-COVID conditions Strengthening QHSLab’s Business...
ORYZON to Present Preliminary Blinded Aggregate Safety Data From Vafidemstat’s Ongoing Phase IIb PORTICO Trial in Borderline Personality Disorder
At the 10th European Conference on Mental Health (ECMH)Company expects to perform an interim analysis in 1Q23MADRID, Spain and BOSTON,...
CloudMD’s TAiCBT Results in Significant Improvement for PTSD Across Symptom Severity Levels, Trauma Types and Demographics
Recent research study demonstrates that the majority of clients experience reliable improvement in symptoms after just two months of treatmentVANCOUVER,...
Mindset Pharma Receives Scientific Advice from UK Regulator Facilitating Advancement of Phase 1 First-In-Human Clinical Trial Plan for Its Lead Clinical Candidate, MSP-1014
TORONTO, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”),...
BrainsWay Announces Significant Private Insurance Coverage from Cigna Corporation for the Treatment of OCD Utilizing Deep TMS™
Cigna® Issues Favorable Policy for Deep TMS to Address Medication-Resistant Obsessive-Compulsive DisorderBURLINGTON, Mass. and JERUSALEM, Israel, Sept. 14, 2022 (GLOBE...